Contact Medical Affairs
Contact Medical Affairs
Medical information resources and request forms are being prepared for launch.
Medical Affairs resources coming soon.
The medical information library, MIRF, and MSRF request workflows will be available here soon.
- Medical information library
- Medical Information Request Form
- Medical Science Review Form
INDICATION
LETYBO® (letibotulinumtoxinA-wlbg) is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
IMPORTANT SAFETY INFORMATION
WARNING: DISTANT SPREAD OF TOXIN EFFECT
The effects of all botulinum toxin products, including LETYBO®, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. LETYBO® is not approved for the treatment of spasticity or any conditions other than glabellar lines.
CONTRAINDICATIONS
LETYBO® contraindications include known hypersensitivity to any botulinum toxin preparation or to any of the components in the LETYBO® formulation and infection at the injection site.
WARNINGS AND PRECAUTIONS
Spread of toxin effects; swallowing and breathing difficulties can lead to death. Seek immediate medical attention if respiratory, speech or swallowing difficulties occur. The potency Units of LETYBO® are not interchangeable with other preparations of botulinum toxin products. Potential serious adverse reactions after LETYBO® injections for unapproved uses. If a hypersensitivity reaction occurs, discontinue LETYBO® and immediately initiate appropriate therapy. Adverse reports have been received involving the cardiovascular system, some with fatal outcomes. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorder may exacerbate clinical effects of treatment. Use with caution in patients with compromised respiratory function or dysphagia.
ADVERSE REACTIONS
The most common adverse reaction was headache (2%).
DRUG INTERACTIONS
Co-administration of LETYBO® and aminoglycosides, anticholinergic agents, or any other agents that interfere with neuromuscular transmission may potentiate the effect of LETYBO®; co-administer only with caution and close observation.
USE IN SPECIFIC POPULATIONS
LETYBO® is not recommended for use in children, pregnant or lactating women.
Please see accompanying Letybo® full Prescribing Information, including Boxed Warning and Medication Guide.
US-LETI-2600010 06/2026
Certain images in this material were created using artificial intelligence for illustrative purposes only. Before and After imagery is unretouched and represents actual patients.